Scientific Sessions 2025  /  Groundbreaking Trials in Cardiometabolic Therapeutics  /  Discussant
Logo

American Heart Association

  59
  0

Final ID:

Discussant

  • Lingvay, Ildiko  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Rosenson, Robert  ( MT SINAI SCHOOL MEDICINE , New York , New York , United States )
    • Author Disclosures:
    Ildiko Lingvay: DO have relevant financial relationships ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Consultant:Betagenon:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:Alveus Therapeutics:Active (exists now) ; Consultant:Altimmune:Active (exists now) ; Consultant:AbbVie:Active (exists now) ; Research Funding (PI or named investigator):Roche:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Lilly:Active (exists now) ; Research Funding (PI or named investigator):Dexcom:Active (exists now) | Robert Rosenson: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Consultant:Intercept Pharmaceuticals:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Editas Medicine:Past (completed) ; Consultant:CRISPER Therapeutics:Past (completed) ; Consultant:Arrowhead:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Shanghai Argo Biopharmaceutical Co.:Active (exists now) ; Research Funding (PI or named investigator):89Bio:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Past (completed) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
The Next Era in Cardiometabolic Treatment

Ballantyne Christie

Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial

Bohula Erin, Wang Huei, Cyrille Marcoli, Paiva Da Silva Lima Gabriel, Giugliano Robert, Sabatine Marc, Marston Nicholas, Bhatia Ajay, De Ferrari Gaetano Maria, Leiter Lawrence, Nicolau Jose, Park Jeong-gun, Murphy Sabina, Walsh Emileigh

More abstracts from these authors:
ANGPTL3 inhibitors for reduction of cardiovascular disease risk

Rosenson Robert

How do we SELECT incretin analogues and SUSTAIN their impact? Clinical approaches for short and long-term obesity care

Jastreboff Ania, Lingvay Ildiko

You have to be authorized to contact abstract author. Please, Login
Not Available